Aromatase inhibitors (AIs), with or without gonadotropin-releasing hormone analogs, are the cornerstone of adjuvant endocrine therapy for women with hormone receptor-positive early-stage breast cancer, offering significant reductions in recurrence risk and improving long-term survival. Their use is frequently accompanied by treatment-related toxicities that can adversely affect patients’ quality of life (QoL) and adherence to therapy. Commonly reported side effects include vasomotor symptoms, such as hot flashes; musculoskeletal disorders, such as arthralgia and myalgia; mood disorders; and genitourinary discomfort, such as vaginal dryness and dyspareunia. Additionally, AIs are associated with a heightened risk of bone loss, leading to osteoporosis and fractures, and may have implications for cardiovascular health. Effective management of these adverse events is pivotal in maintaining treatment adherence and preserving QoL. Evidence-based strategies to address these toxicities include pharmacological interventions, such as analgesics for joint pain, bisphosphonates or denosumab for bone health, and hormonal or non-hormonal approaches for vasomotor and genitourinary symptoms. Non-pharmacological measures, including physical activity, dietary adjustments, and complementary therapies, can also help mitigate symptoms. This review examines the broad spectrum of AI-associated toxicities, discusses their clinical implications, and provides an overview of evidence-based management strategies. These insights aim to support clinicians in optimizing patient care while minimizing the toxicities of therapy.

Background Advanced Therapy Medicinal Products (ATMPs), including gene therapies, RNA-based therapeutics, engineered cellular platforms and tissue-engineered products, are transforming contemporary biomedicine. Their translation, however, remains exposed to manufacturing complexity, regulatory uncertainty, clinical evidence limitations, reimbursement ambiguity and hospital adoption constraints. The traditional valley of death metaphor captures a funding discontinuity between discovery and commercialization, but it is insufficient for ATMPs because uncertainty reappears at multiple inflection points and interacts with capital intensity over long development horizons. Main body This review introduces Translational Uncertainty Load (TUL) as a conceptual lens to describe the cumulative burden of unresolved scientific, manufacturing, regulatory, clinical-delivery, economic, and adoption-related uncertainty that persists across successive translational nodes. Building on entrepreneurial finance and innovation ecosystem theory, we argue that ATMP translation requires more than additional funding. Specialist venture capital can convert uncertainty into staged milestones; corporate venture capital can contribute complementary assets such as manufacturing, regulatory and market-access capabilities; specialized life sciences business angel groups may support early screening, mentoring and follow-on readiness when embedded in credible networks; and heterogeneous club deals can combine public grants, venture capital, corporate investors, big pharma partners, technology transfer offices, vertical incubators, clinical infrastructures, Good Manufacturing Practice (GMP) partners and Health Technology Assessment (HTA) expertise. We further argue that disease typology moderates capital formation: ultra-rare diseases, rare diseases, oncological diseases, common chronic diseases and platform technologies create different TUL profiles and therefore require different financing architectures. Conclusions Reframing advanced therapy translation through TUL shifts the managerial and policy agenda from acceleration toward uncertainty compression. Hybrid innovation ecosystems may operate as translational infrastructures that transform biomedical discovery into clinically deliverable, financeable, and accountable therapeutic pathways by aligning capital, regulatory strategy, manufacturing capacity, patient selection, referral pathways, toxicity management, and long-term follow-up.